One of the most basic needs of investigators studying skin disease is the ability to use tissue sections to analyze the pathological changes at the tissue and cellular level. This analysis requires access to specialized equipment for tissue processing and to highly trained personnel, neither of which can be afforded by most research laboratories. Furthermore, since qualitative and quantitative evaluation of skin and skin appendages requires precise and reproducible orientation of skin sections, histology services not specialized in skin generally produce skin sections of substandard quality. Therefore, the objective of the Morphology and Phenotyping Core is to provide investigators with the tools and expertise to process and analyze skin samples. The Core provides education as well as research and technical consultations to investigators. Further, the Core owns the equipment necessary to process and section skin samples, and employs histology technicians trained in handling skin samples. Thus, the Core is able to provide investigators with high-quality processing and sectioning of skin samples as well as with the preparation of basic histological stains. Whereas histological analysis of skin samples represents the first step in analyzing skin phenotypes, subsequent analyses include immunostaining for various markers of skin proliferation and differentiation. The Core possesses a wide variety of custom-made antibodies that recognize such markers and will provide investigators with immunostaining services using these antibodies. Finally, the Core will offer consultation services by dermatopathologists aimed at assisting investigators with the interpretation of skin phenotypes.

Public Health Relevance

The Morphology and Phenotyping Core will enable UCAMC-SDRC members to analyze how skin structure and function are affected in various human skin diseases and in mouse models designed to mimic these disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Center Core Grants (P30)
Project #
2P30AR057212-06
Application #
8753457
Study Section
Special Emphasis Panel (ZAR1-KM (M1))
Project Start
Project End
Budget Start
2014-08-20
Budget End
2015-07-31
Support Year
6
Fiscal Year
2014
Total Cost
$124,224
Indirect Cost
$44,101
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Cao, Yu; Liu, Han; Gao, Liwei et al. (2018) Cooperation Between Pten and Smad4 in Murine Salivary Gland Tumor Formation and Progression. Neoplasia 20:764-774
Mukherjee, Nabanita; Strosnider, Andrew; Vagher, Bay et al. (2018) BH3 mimetics induce apoptosis independent of DRP-1 in melanoma. Cell Death Dis 9:907
Kogut, Igor; McCarthy, Sandra M; Pavlova, Maryna et al. (2018) High-efficiency RNA-based reprogramming of human primary fibroblasts. Nat Commun 9:745
Riching, Andrew S; Zhao, Yuanbiao; Cao, Yingqiong et al. (2018) Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes. J Vis Exp :
Ravindran Menon, Dinoop; Luo, Yuchun; Arcaroli, John J et al. (2018) CDK1 Interacts with Sox2 and Promotes Tumor Initiation in Human Melanoma. Cancer Res 78:6561-6574
Shah, Khadim; Mehmood, Sabba; Jan, Abid et al. (2017) Sequence variants in nine different genes underlying rare skin disorders in 10 consanguineous families. Int J Dermatol 56:1406-1413
Birlea, Stanca A; Costin, Gertrude-E; Roop, Dennis R et al. (2017) Trends in Regenerative Medicine: Repigmentation in Vitiligo Through Melanocyte Stem Cell Mobilization. Med Res Rev 37:907-935
Zhai, Z; Liu, W; Kaur, M et al. (2017) NLRP1 promotes tumor growth by enhancing inflammasome activation and suppressing apoptosis in metastatic melanoma. Oncogene 36:3820-3830
Gaskill, Christa F; Carrier, Erica J; Kropski, Jonathan A et al. (2017) Disruption of lineage specification in adult pulmonary mesenchymal progenitor cells promotes microvascular dysfunction. J Clin Invest 127:2262-2276
Mukherjee, Nabanita; Lu, Yan; Almeida, Adam et al. (2017) Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells. Oncotarget 8:46801-46817

Showing the most recent 10 out of 61 publications